Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia (CLL) have a 29- to 36-fold increased risk of invasive pneumococcal disease (IPD) compared to healthy adults. Therefore, most guidelines recommend vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valen...

Descripción completa

Detalles Bibliográficos
Autores principales: Haggenburg, Sabine, Garcia Garrido, Hannah M., Kant, Iris M. J., Van der Straaten, Hanneke M., De Boer, Fransien, Kersting, Sabina, Issa, Djamila, Te Raa, Doreen, Visser, Hein P. J., Kater, Arnon P., Goorhuis, Abraham, De Heer, Koen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/
https://www.ncbi.nlm.nih.gov/pubmed/37515017
http://dx.doi.org/10.3390/vaccines11071201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385862/
https://www.ncbi.nlm.nih.gov/pubmed/37515017
http://dx.doi.org/10.3390/vaccines11071201

Ejemplares similares